Dr. Pienta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
401 N. Broadway
Baltimore, MD 21231Phone+1 410-955-8964- Is this information wrong?
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1988 - 1991
- University of ChicagoResidency, Internal Medicine, 1986 - 1988
- Johns Hopkins University School of MedicineClass of 1986
Certifications & Licensure
- NY State Medical License 1987 - Present
- MD State Medical License 1988 - 2025
- MI State Medical License 1991 - 2025
- IL State Medical License 1986 - 1989
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2020
- America's Top Doctors for Cancer Castle Connolly, 2005-2020
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Oct 01
- Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer Start of enrollment: 2005 Dec 01
- S0916, MLN1202 in Treating Patients With Bone Metastases Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Punctuational evolution is pervasive in distal site metastatic colonization.George Butler, Sarah R Amend, Robert Axelrod, Chris Venditti, Kenneth J Pienta> ;Biorxiv. 2024 Apr 11
- Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues.Wanyoung Lim, Inwoo Hwang, Jiande Zhang, Zhenzhong Chen, Jeonghun Han, Jaehyung Jeon, Bon-Kyoung Koo, Sangmin Kim, Jeong Eon Lee, Youngkwan Kim, Sarah R Amend, Robert ...> ;Elife. 2024 Mar 27
- Drug-resilient Cancer Cell Phenotype Is Acquired via Polyploidization Associated with Early Stress Response Coupled to HIF2α Transcriptional Regulation.Christopher Carroll, Auraya Manaprasertsak, Arthur Boffelli Castro, Hilda van den Bos, Diana C J Spierings, René Wardenaar, Anuraag Bukkuri, Niklas Engström, Etienne B...> ;Cancer Research Communications. 2024 Mar 7
- Join now to see all
Journal Articles
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerEmmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
- Prostate-Specific Markers to Identify Rare Prostate Cancer Cells in Liquid BiopsiesKenneth Pienta, MD, Nature
- Cooperation Among Cancer Cells: Applying Game Theory to CancerKenneth Pienta, MD, Nature
- Join now to see all
Press Mentions
- The Prostate Cancer Foundation Announces 2020 Challenge Awards Totaling More Than $11 Million for Prostate Cancer ResearchDecember 31st, 2020
- A Prostate Cancer Community: Driving Access to Resources for Patients and Providers of Care - Felix Feng and Charles RyanSeptember 24th, 2020
- Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem EngineersMarch 4th, 2020
- Join now to see all
Grant Support
- Prostate Cancer Induces CCL2 Expression And Transforms The Bone MicroenviNational Cancer Institute2009–2012
- Mechanisms Of Prostate Cancer Dormancy In The Bone Marrow NicheNational Cancer Institute2011
- Reactive Stroma And Tumor Associated Macrophages In Prostate Cancer ProgressionNational Cancer Institute2010–2011
- Carryover From Year -09 For Phase II Evaluation Of EMD 12194National Cancer Institute2008–2011
- Administration CoreNational Cancer Institute2008–2011
- Spore In Prostate CancerNational Cancer Institute1995–2011
- Annual Meeting For The Clinical Research Ethics Key Function CommitteeNational Center For Research Resources2010
- CTSA Infrastructure For Pediatric ResearchNational Center For Research Resources2009–2010
- CTSA Infrastructure For Clinical TrialsNational Center For Research Resources2009–2010
- CTSA Infrastructure For AIDS ResearchNational Center For Research Resources2009–2010
- Michigan Institute For Clinical And Health Research (MICHR) (UL1)National Center For Research Resources2008–2010
- Michigan Institute For Clinical And Health Research (MICHR) (Ul1): (BPCA)National Center For Research Resources2009
- Michigan Institute For Clinical And Health Research (MICHR) (TL1)National Center For Research Resources2008–2009
- Michigan Institute For Clinical And Health Research (MICHR) (KL2)National Center For Research Resources2008–2009
- The Therapeutic Potential, Pharmacology And Toxiciity Of Promising Small-MoleculeNational Cancer Institute2005–2009
- PAR1 In Prostate Cancer Cell Motility And InvasionNational Cancer Institute2004–2008
- S.P.O.R.E. In Prostate CancerNational Cancer Institute2003–2007
- Molecular Changes Associated With PCA Bone MetastasesNational Cancer Institute2003–2006
- Urology Research Training GrantNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2004
- Pilot--Prostate Cancer And Urological OncologyNational Cancer Institute2001–2002
- Inhibition Of Human Prostate Cancer MetastasisNational Cancer Institute1998–2002
- Developmental Research ProgramNational Cancer Institute1998–2002
- Prostate Cancer Metastasis To BoneNational Cancer Institute1999–2000
- Nuclear Matrix As A Target For Prostate Cancer ChemotherapyNational Center For Research Resources1998–1999
- Phase II Clinical Trials Of New Chemopreventive AgentsDivision Of Cancer Prevention And Control1998
- Aminocamptothecin (9 Ac/Dma) In Hormone Refractory Prostate CancerNational Center For Research Resources1997
- Inhibition Of Human Prostate-Cancer Metastasis By Modified Citrus PectinNational Cancer Institute1996–1997
- Emcyt, VP16, And Taxol For Metastatic Prostate CancerNational Cancer Institute1996–1997
- Organization Of DNA In Cancer CellsNational Cancer Institute1994–1996
- Nuclear Matrix As A Cancer Chemotherapy TargetNational Cancer Institute1994
- The Organization Of DNA In Cancer CellsNational Cancer Institute1993
- Nuclear Matrix As A Cancer Chemotherapy TargetNational Cancer Institute1992–1993
- Organization Of DNA In Cancer CellsNational Cancer Institute1992
Professional Memberships
- Member
Hospital Affiliations
- University of Michigan Medical CenterAnn Arbor, Michigan
- Johns Hopkins HospitalBaltimore, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: